2017 European guideline for the screening,prevention and initial management of hepatitis B and C infections in sexual health settings

Abstract

This guideline updates the 2010 European guideline for the management of hepatitis B and C virus infections. It is primarily intended to provide advice on testing, prevention and initial management of viral hepatitis B and C for clinicians working in sexual health clinical settings in European countries. The guideline is in a new question and answer format based on clinical situations, from which population/intervention/comparison/outcome questions were formulated. Updates cover areas such as epidemiology, point-of-care tests for hepatitis B, hepatitis C risk and ‘chemsex’, and HIV pre-exposure prophylaxis and hepatitis B. We have also included a short paragraph on hepatitis E noting there is no evidence for sexual transmission. The guideline has been prepared in accordance with the Europe protocol for production available at http://www.iusti.org/regions/europe/pdf/2017/ProtocolForProduction2017.pdf

Keywords

Diagnosis Europe hepatitis B hepatitis C immunisation standard of care

Get full access to this article

View all access options for this article.

References

Brook

Soriano

V and

Bergen

European guideline for the management of hepatitis B and C virus infections, 2010. Int J STD AIDS 2010; 21: 669–678.

World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection, http://apps.who.int/iris/bitstream/10665/154590/1/9789241549059_eng.pdf (2015, accessed 12 December 2016).

World Health Organization. Guidelines for the screening care and treatment of persons with chronic hepatitis C infection, http://apps.who.int/iris/bitstream/10665/205035/1/9789241549615_eng.pdf (2016, accessed 12 December 2016).

European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol 2017; 66: 153–194.

European Centre for Disease Prevention and Control. Systematic review on hepatitis B and C prevalence in the EU/EEA. Stockholm: ECDC, https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/systematic-review-hepatitis-B-C-prevalence.pdf (2016, accessed 10 December 2016).

Locarnini

Hatzakis

Chen

D-S

et al . Strategies to control hepatitis B: public policy, epidemiology, vaccine and drugs. J Hepatol 2015; 62: S76–S86.

Pitasi

Bingham

Sey

et al . Hepatitis B virus (HBV) infection, immunity and susceptibility among men who have sex with men (MSM), Los Angeles County, USA. AIDS Behav 2014; 18: 248–255.

van Rijckevoorsel

Whelan

Kretschmar

et al . Targeted vaccination programme successful in reducing acute hepatitis B in men having sex with men in Amsterdam, the Netherlands. J Hepatol 2013; 59: 1177–1183.

van Houdt

Bruisten

Speksnijder

et al . Unexpectedly high proportion of drug users and men having sex with men who develop chronic hepatitis B infection. J Hepatol 2012; 57: 529–533.

10.

Ward

Day

S and

Weber

Risky business: health and safety in the sex industry over a 9 year period. Sex Transm Infect 1999; 75: 340–343.

11.

Struve

Giesecke

Lindh

et al . Heterosexual contact as a major route for transmission of acute hepatitis B amongst adults. J Infect 1990; 20: 111–121.

12.

Nelson

Mathers

Cowie

et al . Global epidemiology of hepatitis B and C in people who inject drugs: results of systematic reviews. Lancet 2011; 378: 571–583.

13.

Hahne

Ramsay

Balogun

et al . Incidence and routes of transmission of hepatitis B virus in England Wales, 1995–2000: implications for immunization policy. J Clin Virol 2004; 29: 211–220.

14.

Kleinman

Lelie

N and

Busch

MP.

Infectivity of human immunodeficiency virus-1, hepatitis C virus and hepatitis B virus and risk of transmission by transfusion. Transfusion 2009; 49: 2454–2489.

15.

Stramer

Wend

Candotti

et al . Nucleic acid testing to detect HBV in blood donors. N Engl J Med 2011; 364: 236–247.

16.

Buchner

Du Plessis

Reynders

et al . Nosocomial outbreak of hepatitis B virus infection in a pediatric hematology and oncology unit in South-Africa: epidemiological investigation and measures to prevent further transmission. Pediatr Blood Cancer 2015; 62: 1914–1919.

17.

Kliner

Dardamissis

Abrajham

et al . Identification, investigation and management of patient-to-patient hepatitis B transmission within an inpatient renal word in North-West England. Clin Kidney J 2015; 8: 102–106.

18.

Hou

Cao

Is mother-to-infant transmission the most important factor for persistent HBV infection?.

Emerg Microbes Infect 2015; 4: e30.

19.

Gentile

Biorgia

Vertical transmission of hepatitis B virus: challenges and solutions. Int J Womens Health 2014; 6: 605–611.

20.

Nayagam

Thursz

Sicuri

et al . Requirements for global elimination of hepatitis B: a modelling study. Lancet Infect Dis 2016; 16: 1399–1408.

21.

Urbanus

van Houdt

van de Laar

et al . Viral hepatitis among men who have sex with men, epidemiology and public health consequences. Euro Surveill 2009; 14: 1560.

22.

Shin

Sung

Park

SH.

Immune responses and immunopathology in acute and chronic viral hepatitis. Nat Rev Immunol 2016; 16: 509–523.

23.

McIntyre

Clinical presentation of acute viral hepatitis. Br Med Bull 1990; 46: 533–547.

24.

Hyams

KC.

Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis 1995; 20: 992–1000.

25.

Zuure

Hahné

van de Laar

et al.

Blood borne and sexual transmission: hepatitis B and C. In: Krämer

Kretzschmar

Krickeberg

(eds) Modern infectious disease epidemiology – concepts, methods, mathematical models and public health. New York: Springer, 2010, pp. 333–356.

26.

Phung

Sogni

P and

Launay

Hepatitis B and HIV co-infection. World J Gastroenterol 2014; 20: 17360–17367.

27.

Chiang

Chi

et al . Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination. Hepatology 2004; 40: 1415–1420.

28.

TH and

Chen

PJ.

Emerging hepatitis B virus infection in vaccinated populations: a rising concern?.

Emerg Microbes Infect 2012; 1: e27.

29.

van de Laar

Marijt-van der Kreek

Molenaar-deBacker

et al . The yield of universal antibody to hepatitis B core antigen donor screening in the Netherlands, a hepatitis B virus low-endemic country. Transfusion 2015; 55: 1206–1213.

30.

Schmidt

Nübling

Scheibauer

et al . Anti-HBc screening of blood donors: a comparison on nine anti-HBc tests. Vox Sang 2006; 91: 237–243.

31.

Hollinger

FB.

Hepatitis B virus infection and transfusion medicine: science and the occult. Transfusion 2008; 48: 1001–1026.

32.

Seo

Whang

Song

et al . Occult hepatitis B virus and blood transfusion. World J Hepatol 2015; 7: 600–606.

33.

Johannessen

Where are we with point-of-care testing?.

J Viral Hepat 2015; 22: 362–365.

34.

Shivkumar

Peeling

Jafari

et al . Rapid point-of-care first-line screening tests for hepatitis B infection: a meta-analysis of diagnostic accuracy (1980–2010). Am J Gastroenterol 2012; 107: 1306–1313.

35.

Huo

Huang

et al . Evidence of transmission of hepatitis B to spouses from sequence analysis of the viral genome. J Gastroenterol Hepatol 1998; 13: 1138–1142.

36.

Gerlich

WH.

Medical Virology of Hepatitis B: how it began and where we are now.

Virol J 2013; 10: 239.

37.

Gilson

de Ruiter

Waite

et al . Hepatitis B virus infection in patients attending a genitourinary medicine clinic: risk factors and vaccination coverage. Sex Transm Infect 1998; 74: 110–115.

38.

Hyams

Phillips

IA and

Tejada

Hepatitis B in a highly active prostitute population: evidence for a low risk of antigenaemia. J Infect Dis 1990; 162: 295–298.

39.

Public Health England. Hepatitis B In: Immunisation against infectious disease, https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/691849/Green_book_chapter_18_prior_aug17.pdf (2016, accessed 24 March 2018).

40.

Walsh

Maguire

H and

Carrington

Outbreak of hepatitis B in a acupuncture clinic. Commun Dis Public Health 1999; 2: 137–140.

41.

Palmovic

Crnjakovic-Palmovic

et al . Prevention of hepatitis B virus (HBV) infection in health-care workers after accidental exposure: a comparison of two prophylactic schedules. Infection 1993; 21: 42–45.

42.

Vogt

Perz

Van-Houten

Jr et al . An outbreak of hepatitis B virus infection among methamphetamine injectors: the role of sharing injection drug equipment. Addiction 2006; 101: 726–730.

43.

Cramp

Grundy

Perinpanayagam

et al . Seroprevalence of hepatitis B and C virus in two institutions caring for mentally handicapped adults. J Roy Soc Med 1996; 89: 401–402.

44.

Wallace

RA.

Clinical audit of gastrointestinal conditions occurring among adults with Down syndrome attending a specialist clinic. J Intellect Dev Disabil 2007; 32: 45–50.

45.

Daskalopoulou

Rodger

Philips

et al . Recreational drug use, polydrug use, and sexual behaviour in HIV-diagnosed men who have sex with men in the UK: results from the cross-sectional ASTRA study. Lancet HIV 2014; e22–e31.

46.

Hope

Harris

McVeigh

et al . Risk of HIV and Hepatitis B and C over time among men who inject image and performance enhancing drugs in England and Wales: results from cross-sectional prevalence surveys. J Acquir Immune Defic Syndr 2016; 71: 331–337.

47.

Connor

Blatter

Beran

et al . Rapid and sustained immune response against hepatitis A and B achieved with combined vaccine using an accelerated administration schedule. J Travel Med 2007; 14: 9–15.

48.

Ahmed

Volpellier

L and

Forster

The use of the super accelerated hepatitis B vaccination regimen in a north London sexual assault referral centre (SARC). J Forensic Leg Med 2007; 14: 72–74.

49.

Keystone

JS and

Hershey

JH.

The underestimated risk of hepatitis A and hepatitis B: benefits of an accelerated vaccination schedule. Int J Infect Dis 2008; 12: 3–11.

50.

Kallinowski

Jilg

Buchholz

et al . Immunogenicity of an accelerated vaccination regime with a combined hepatitis A/B vaccine in patients with chronic hepatitis C. Z Gastroenterol 2003; 41: 983–990.

51.

Poorolajal

Mahmoodi

Majdzadeh

et al . Long-term protection provided by hepatitis B vaccine and need for booster dose: a meta-analysis. Vaccine 2010; 28: 623–631.

52.

Rey

Piroth

Wendling

M-J

et al . Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial. Lancet Infect Dis 2015; 15: 1283–1291.

53.

Kuria

Brook

G and

McSorley

The effect of electronic patient records on hepatitis B vaccination completion rates at a genitourinary medicine clinic.

Int J STD AIDS 2016; 27: 486–489.

54.

Wielding

A and

Clutterbuck

An audit of hepatitis B vaccination for men who have sex with men before and after sexual health service integration. Int J STD AIDS 2016; 27: 898–900.

55.

Sun

Yan

et al . Lamivudine treatment is associated with improved survival in fulminant hepatitis B. Liver Int 2011; 31: 499–506.

56.

De Socio

Sgrelli

Tosti

et al . Severe acute hepatitis B treated with entecavir. Mediterr J Hematol Infect Dis 2011; 3: e2011010.

57.

Oxman

Scott

Sellors

et al . Partner notification for sexually transmitted diseases: an overview of the evidence. Canadian J Pub Health 1994; 85: S41–S47.

58.

McClean

Radcliffe

Sullivan

et al. 2012 BASHH statement on partner notification for sexually transmissible infections, www.bashh.org/documents/4445.pdf (2012, accessed 4 September 2016).

59.

Public Health England. Acute hepatitis B (England): annual report for 2014, www.gov.uk/government/uploads/system/uploads/attachment_data/file/457408/hpr3015_hbv-ann.pdf (2015, accessed 4 September 2016).

60.

Zuckerman

JN.

Review: hepatitis B immune globulin for prevention of hepatitis B infection. J Med Virol 2007; 79: 919–921.

61.

Health Protection Agency, Public Health England. Immunoglobulin handbook: chapter 6 – hepatitis B, www.gov.uk/government/uploads/system/uploads/attachment_data/file/327768/Hepatitis_B_immunoglobulin_Oct_2008.pdf (2008, accessed 4 September 2016).

62.

Mast

Weinbaum

Fiore

et al . A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006; 55: 1–25.

63.

Baral

Sherman

Millson

et al . Vaccine immunogenicity in injecting drug users: a systematic review. Lancet Infect Dis 2007; 7: 667–674.

64.

Cornberg

Protzer

Petersen

et al . Prophylaxis, diagnosis and therapy of hepatitis B virus infection – the German guideline. Z Gastroenterol 2011; 49: 871–930.

65.

McMahon

BJ.

The natural history of chronic hepatitis B virus infection. Semin Liver Dis 2004; 24: 17–21.

66.

Hoofnagle

JH.

Chronic hepatitis B. N Engl J Med 1990; 323: 337–928.

67.

Papatheodoridis

Manolakopoulos

Dusheiko

et al . Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis 2008; 8: 167–178.

68.

National Institute for Health and Care Excellence. Hepatitis B (chronic): diagnosis and management of chronic hepatitis B in children, young people and adults, www.nice.org.uk/Guidance/CG165 (2013, accessed 4 September 2016).

69.

European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2012; 57: 167–185.

70.

Thomas

HC.

Best practice in the treatment of chronic hepatitis B: a summary of the European Viral Hepatitis Educational Initiative (EVHEI). J Hepatol 2007; 47: 588.

71.

Hosaka

Suzuki

Kobayashi

et al . Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013; 58: 98–107.

72.

Kim

Berg

Loomba

et al . Long term tenofovir disoproxil fumarate (TDF) therapy and the risk of hepatocellular carcinoma. J Hepatol 2013; 58: S19.

73.

Lai

Gane

Liaw

et al . Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576–2588.

74.

Giovanna

Bortolotti

F and

Francesco

Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48: 335–352.

75.

Lin

Verslype

van Pelt

et al . Viral interaction and clinical implications of coinfection of hepatitis C virus with other hepatitis viruses. Eur J Gastroenterol Hepatol 2006; 18: 1311–1319.

76.

Chiaramonte

Stroffolini

Vian

et al . Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 1999; 85: 2132–2137.

77.

Thio

Seaberg

Skolasky

Jr et al . HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360: 1921–1926.

78.

Hoffmann

CJ and

Thio

CL.

Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis 2007; 7: 402–409.

79.

Puoti

Torti

Bruno

et al . Natural history of chronic hepatitis B in co-infected patients. J Hepatol 2006; 44: S65–S70.

80.

Rockstroh

JK.

Influence of viral hepatitis on HIV infection. J Hepatol 2006; 44: S25–S27.

81.

Sagnelli

Coppola

Pisaturo

et al . Clinical and virological improvement of hepatitis B virus-related or hepatitis C virus related chronic hepatitis with concomitant hepatitis A virus infection. Clin Infect Dis 2006; 42: 1536–1543.

82.

Chu

CJ and

Lee

SD.

Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol 2008; 23: 512–520.

83.

Sherman

Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 2005; 25: 143–154.

84.

Ward

Lee

Experience of acute hepatitis C and HIV co-infection in an inner city clinic in the UK. J Int AIDS Soc 2014; 17: 19639.

85.

Kumar

Chauhan

Gupta

Spontaneous increases in alanine transaminase levels in asymptomatic chronic hepatitis-B virus infected patients. Gastroenterology 2009; 136: 1272–1280.

86.

Solomon

et al . The safety of HIV pre-exposure prophylaxis in the presence of hepatitis B infection. In: 8th International AIDS Society conference on HIV pathogenesis, treatment, and prevention (IAS 2015), 19–22 July, Vancouver, Canada, abstract TUAC0201, 2015.

87.

Gower

Estes

Blach

et al . Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014; 61: S45–S57.

88.

European AIDS Clinical Society Guidelines v 8.1, www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html (2016, accessed 15 November 2016).

89.

Scott

JD.

Molecular diagnostics of hepatitis C virus infection: a systematic review. JAMA 2007; 297: 724–732.

90.

Thomson

Nastouli

Main

et al . Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV. AIDS 2009; 23: 89–93.

91.

Vanhommerig

Thomas

van der Meer

et al . Hepatitis C virus (HCV) antibody dynamics following acute HCV infection and reinfection among HIV-infected men who have sex with men. Clin Infect Dis 2014; 59: 1678–1685.

92.

Glynn

Wright

Kleinman

et al . Dynamics of viremia in early HCV infection. Transfusion 2005; 45: 994–1002.

93.

Medici

Furlini

Rodella

et al . Hepatitis C virus core antigen: analytical performances, correlation with viremia and potential applications of a quantitative, automated immunoassay. J Clin Virol 2011; 51: 264–269.

94.

Medici

Chezzi

de Conto

et al . Evolving strategy for HCV testing in an Italian tertiary care hospital. J Clin Virol 2016; 77: 92–98.

95.

Cresswell

Fisher

Hughes

et al . Hepatitis C core antigen testing: a reliable, quick and potentially cost-effective alternative to Hepatitis C polymerase chain reaction in diagnosing acute hepatitis C virus infection. Clin Infect Dis 2015; 60: 263–266.

96.

Vanhommerig

JW.

Evaluation of a hepatitis virus (HCV) antigen assay for routine HCV screening among MSM infected with HIV. J Virol Meth 2015; 213: 147–150.

97.

Matthews

Hellard

Haber

et al . Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C. Clin Infect Dis 2009; 48: 650–658.

98.

Vanhommerig

et al . Sexual transmission of HCV among HIV-infected MSM: a case-control study. Open Forum Infect Dis 2015; 2: ofv115.

99.

Danta

et al . Recent epidemic of acute HCV in HIV-positive MSM linked to high-risk sexual behaviours. AIDS 2007; 21: 983–991.

100.

Apers

et al . Risk factors for HCV acquisition among HIV-positive MSM in Belgium. J Acquir Immune Defic Syndr 2015; 68: 585–593.

101.

Schmidt

Rockstroh

Vogel

et al . Trouble with bleeding: risk factors for acute hepatitis C among HIV-positive gay men from Germany – a case-control study. PLoS One 2011; 6: e17781.

102.

Fierer

Factor

Uriel

et al . Sexual transmission of hepatitis C virus among HIV-infected MSM in New York City, 2005–2010. MMWR Morb Mortal Wkly Rep 2011; 60: 945–950.

103.

Marcellin

Lorente

Demoulin

et al . Comparison of risk factors in HIV-infected men who have sex with men, coinfected or not with hepatitis C virus (ANRS VESPA2 French cross-sectional national survey). Sex Transm Infect 2015; 91: 21–23.

104.

Hagan

et al . Incidence of sexually transmitted hepatitis C virus infection in HIV-positive men who have sex with men. AIDS 2015; 29: 2335–2345.

105.

Lambers

FAE

Prins

Thomas

et al . Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM. AIDS 2011; 25: F21–F27.

106.

Sacks-Davis

Grebely

Dore

et al . Hepatitis C Virus reinfection and spontaneous clearance of reinfection – the InC3 Study. J Infect Dis 2015; 212: 1407–1419.

107.

Vandelli

Renzo

Romanò

et al . Lack of evidence of sexual transmission of Hepatitis C among monogamous couples: results of a 10-year prospective follow-up study. Am J Gastroenterology 2004; 99: 855–859.

108.

Terrault

Dodge

Murphy

et al . Sexual transmission of hepatitis C virus among monogamous heterosexual couples: The HCV partners study. Hepatology 2013; 57: 881–889.

109.

van de Laar

Paxton

Zorgdrager

et al . Sexual transmission of HCV in HIV-negative MSM: a series of case reports. Sex Transm Dis 2011; 38: 102–104.

110.

Blaxhult

Samuelson

Ask

et al . Limited spread of hepatitis C among HIV-negative men who have sex with men in Stockholm, Sweden. Int J STD AIDS 2015; 25: 493–495.

111.

Vanhommerig

Stolte

Lambers

et al . Stabilizing incidence of hepatitis C virus infection among men who have sex with men in Amsterdam. J AIDS 2014; 66: e111–e115.

112.

McFaul

Maglaouhi

Nzuruba

et al . Acute hepatitis C infection in HIV-negative men who have sex with men. J Viral Hepat 2015; 22: 535–538.

113.

Ward

C and

Lee

Should we offer routine hepatitis C antibody testing in men who have sex with men?.

J Int AIDS Soc 2014; 17: 19591.

114.

Kaplan-Lewis

E and

Fierer

DS.

Acute HCV in HIV-infected MSM: Modes of acquisition, liver fibrosis, and treatment. Curr HIV/AIDS Rep 2015; 12: 317–325.

115.

Wiessing

Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS One 2014; 9: e103345.

116.

Palmateer

NE.

Review and meta-analysis of the association between self-reported sharing of needles/syringes and HCV prevalence and incidence among PWID in Europe. Int J Drug Policy 2013; 24: 85–100.

117.

Pouget

ER.

Meta-analysis of HCV seroconversion in relation to shared syringes and drug preparation equipment. Addiction 2012; 107: 1057–1065.

118.

Hope

Cullen

Smith

et al . Is the recent emergence of mephedrone injecting in the United Kingdom associated with elevated risk behaviours and blood borne virus infection? Euro Surveill 2016; 21: 30225.

119.

Hagan

et al . A systematic review and meta-analysis of interventions to prevent HCV in PWID. J Infect Dis 2011; 204: 74–83.

120.

van den Berg

Smit

van Brussel

et al . Full participation in harm reduction programmes is associated with a decreased risk for HIV and HCV: evidence from the Amsterdam Cohort Studies among drug users. Addiction 2007; 109: 1454–1462.

121.

Turner

KME.

The impact of needle and syringe provision and opiate substitution therapy on the incidence of HCV in injecting drug users: pooling of UK evidence. Addiction 2011; 106: 1978–1988.

122.

Vickerman

Martin

Turner

et al . Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in HCV prevalence? Model projections for different epidemic settings. Addiction 2012; 107: 1984–1995.

123.

Lambers

FAE

Prins

Davdiovich

et al . High awareness of HCV but limited knowledge of HCV complications among HIV-positive and HIV-negative MSM. AIDS Care 2014; 26: 416–424.

124.

Brener

Murphy

Cama

et al . Hepatitis C risk factors, attitudes and knowledge among HIV-positive, HIV-negative and HIV-untested gay and bisexual men in Australia. Sex Health 2015; 12: 411–417.

125.

Le Talec

JY.

When ‘raw sex’turns to a ‘raw deal’… taking the opportunity to think about sex? Interviews with HIV-positive gay men diagnosed with acute HCV. Cult Health Sex 2013; 15: 1133–1147.

126.

Hickman

Hepatitis C virus treatment as prevention in PWID: testing the evidence. Curr Opin Infect Dis 2015; 28: 576–582.

127.

Aspinall

Doyle

Corson

et al . Targeted HCV antibody testing interventions: a systematic review and meta-analysis. Eur J Epidemiol 2015; 30: 115–129.

128.

Martin

Vickerman

Gore

et al . The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of DAAs as treatment for prevention. Curr Opin HIV AIDS 2015; 10: 374–380.

129.

Roberts

et al . Prevention of hepatitis C by screening and treatment in U.S. Prisons. Ann Intern Med 2016; 164: 84–92.

130.

Dwyre

Fernando

LP and

Holland

PV.

Hepatitis B, hepatitis C and HIV transfusion-transmitted infections in the 21st century. Vox Sang 2011; 100: 92–98.

131.

Baumert

Fauvelle

Chen

et al . A prophylactic hepatitis C vaccine: a distant peak still worth climbing. J Hepatol 2014; 61: S33–S43.

132.

World Health Organisation. Prevention and treatment of HIV and other sexually transmitted infections among men who have sex with men and transgender people. Geneva: World Health Organization, www.who.int/hiv/pub/guidelines/msm_guidelines2011/en/ (2011, accessed 18 December 2016).

133.

Chevaliez

S and

Pawlotsky

JM.

Diagnosis and management of chronic viral hepatitis: antigens, antibodies and viral genomes. Best Pract Res Clin Gastroenterol 2008; 22: 1031–1048.

134.

Kamili

Drobeniuc

Araujo

et al . Laboratory diagnostics for hepatitis C virus infection. Clin Infect Dis 2012; 55: S43–S48.

135.

Ansaldi

Orsi

Sticchi

et al . Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World J Gastroenterol 2014; 20: 9633–9652.

136.

Kamal

SM.

Acute hepatitis C: a systematic review. Am J Gastroenterol 2008; 103: 1283–1297.

137.

Mondelli

Cerino

A and

Cividini

Acute hepatitis C: diagnosis and management. J Hepatol 2005; 42: S108–S114.

138.

Santantonio

Wiegand

J and

Gerlach

JT.

Acute hepatitis C: current status and remaining challenges. J Hepatol 2008; 49: 625–633.

139.

Strader

Wright

Thomas

et al . Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147–1171.

140.

Beinhardt

Payer

Datz

et al . A diagnostic score for the prediction of spontaneous resolution of acute hepatitis C virus infection. J Hepatol 2013; 59: 972–977.

141.

European AIDS Treatment Network (NEAT) Acute Hepatitis C Infection Consensus Panel. Acute hepatitis C in HIV infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference. AIDS 2011; 25: 399–409.

142.

McMahon

Pouget

Tortu

Individual and couple-level risk factors for hepatitis C infection among heterosexual drug users: a multilevel dyadic analysis. J Infect Dis 2007; 195: 1572–1581.

143.

Jebbari

Alexander

Ward

et al . Update on lymphogranuloma venereum in the United Kingdom. Sex Transm Infect 2007; 83: 324–326.

144.

Urbanus

Van De Laar

Geskus

et al . Trends in hepatitis C virus infections among MSM attending a sexually transmitted infection clinic; 1995–2010. AIDS 2014; 28: 781–790.

145.

Pramoolsinsap

Acute hepatitis A and immunity to hepatitis A virus in hepatitis B virus carriers and in HBV-or hepatitis C virus-related chronic liver diseases in Thailand. J Viral Hepat 2000; 7: 11–12.

146.

Persico

Perrotta

Persico

et al . Hepatitis C virus carriers with persistently normal ALT levels: biological peculiarities and update of the natural history of liver disease at 10 years. J Viral Hepat 2006; 13: 290–296.

147.

Massard

Ratziu

Thabut

et al . Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol 2006; 44: S19–S24.

148.

Brewer

D and

Hagan

Evaluation of a patient referral contact tracing programme for hepatitis B and C virus infection in drug injectors. Eurosurveillance 2009; 14: 5–9.

149.

Poll

Hepatitis C: the case against routine partner notification. Int J STD AIDS 2013; 24: 165–168.

150.

Benova

Mohamoud

Calvert

et al . Vertical transmission of Hepatitis C virus: systematic review and meta-analysis. Clin Infect Dis 2014; 59: 765–773.

151.

Cottrell

Chou

Wasson

et al . Reducing risk for mother-to-infant transmission of hepatitis C virus: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2013; 158: 109–113.

152.

England

Thorne

Harris

et al . The impact of mode of acquisition on biological markers of paediatric hepatitis C virus infection. J Viral Hepat 2011; 18: 533–541.

153.

Mok

Pembrey

Tovo

et al .; for the European Paediatric Hepatitis C Virus Network. When does mother to child transmission of hepatitis C virus occur?. Arch Dis Child 2005; 90: F156–F160.

154.

Azzari

Moriond

Indolfi

et al . Higher risk of hepatitis C virus perinatal transmission from drug user mothers is mediated by peripheral blood mononuclear cell infection. J Med Virol 2008; 80: 65–71.

155.

Lefilliatre

P and

Villeneuve

JP.

Fulminant hepatitis A in patients with chronic liver disease. Can J Public Health 2000; 91: 168–170.

156.

Deterding

Tegtmeyer

Cornberg

et al . Hepatitis A virus infection suppresses hepatitis C virus replication and may lead to clearance of HCV. J Hepatol 2006; 45: 770–778.

157.

Kao

Liu

Chen

et al . Low incidence of hepatitis C virus transmission between spouses: a prospective study. J Gastroenterol Hepatol 2000; 15: 391–395.

158.

Marincovich

Castilla

del

et al . Absence of hepatitis C virus transmission in a prospective cohort of heterosexual serodiscordant couples. Sex Transm Infect 2003; 79: 160–162.

159.

Boesecke

C and

Page

Direct-acting antiviral-based therapy for acute hepatitis C coinfection. Curr Opin HIV AIDS 2015; 10: 330–336.

160.

Khuroo

MS and

Khuroo

NS.

Transmission of hepatitis E virus in developing countries. Viruses 2016; 8: 253.